当前位置:首页 - 行情中心 - 药康生物(688046) - 财务分析 - 现金流量表

药康生物

(688046)

  

流通市值:70.44亿  总市值:70.44亿
流通股本:4.10亿   总股本:4.10亿

现金流量表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金513,933,061.3307,841,303.42125,542,405.66650,725,751.22
  收到的税费返还11,382.72---
  收到其他与经营活动有关的现金18,342,467.769,912,469.0316,144,303.7723,392,070.17
  经营活动现金流入的平衡项目000.010
  经营活动现金流入小计532,286,911.78317,753,772.45141,686,709.44674,117,821.39
  购买商品、接受劳务支付的现金129,978,572.5290,518,048.1543,044,083.01134,141,161.24
  支付给职工以及为职工支付的现金243,405,353.33171,511,317.4499,705,079.68306,905,206.56
  支付的各项税费17,131,592.711,210,555.782,613,044.4540,587,958.83
  支付其他与经营活动有关的现金54,597,068.5629,248,872.4723,052,108.03102,169,235.23
  经营活动现金流出小计445,112,587.11302,488,793.84168,414,315.17583,803,561.86
  经营活动产生的现金流量净额87,174,324.6715,264,978.61-26,727,605.7390,314,259.53
二、投资活动产生的现金流量:
  取得投资收益收到的现金10,402,185.296,066,539.452,154,024.4423,360,314.79
  处置固定资产、无形资产和其他长期资产收回的现金净额13,00013,00013,000-
  收到的其他与投资活动有关的现金1,735,548,888.9913,387,333.34373,242,333.341,895,315,833.55
  投资活动现金流入小计1,745,964,074.19919,466,872.79375,409,357.781,918,676,148.34
  购建固定资产、无形资产和其他长期资产支付的现金95,760,358.5171,418,745.6532,289,074.17113,677,403.33
  投资支付的现金15,510,00014,010,000-14,000,001
  支付其他与投资活动有关的现金2,228,152,969.181,180,702,135.85720,000,0001,632,105,900
  投资活动现金流出小计2,339,423,327.691,266,130,881.5752,289,074.171,759,783,304.33
  投资活动产生的现金流量净额-593,459,253.5-346,664,008.71-376,879,716.39158,892,844.01
三、筹资活动产生的现金流量:
  取得借款收到的现金255,168,663.99220,450,000119,450,00097,950,000
  收到其他与筹资活动有关的现金11,249,60011,249,600--
  筹资活动现金流入小计266,418,263.99231,699,600119,450,00097,950,000
  偿还债务支付的现金87,902,777.7867,952,777.7867,950,00086,000,000
  分配股利、利润或偿付利息支付的现金48,030,922.512,020,919.81613,696.380,114,031.8
  支付其他与筹资活动有关的现金21,178,064.4411,302,726.934,101,292.3840,780,732.14
  筹资活动现金流出小计157,111,764.7381,276,424.5272,664,988.68206,894,763.94
  筹资活动产生的现金流量净额109,306,499.26150,423,175.4846,785,011.32-108,944,763.94
四、汇率变动对现金及现金等价物的影响54,614.881,744,503.74532,829.53959,889.98
  现金及现金等价物净增加额平衡项目-0.01000
五、现金及现金等价物净增加额-396,923,814.7-179,231,350.88-356,289,481.27141,222,229.58
  加:期初现金及现金等价物余额701,215,442.73701,215,442.73701,225,470.73559,993,213.15
  期末现金及现金等价物余额304,291,628.03521,984,091.85344,935,989.46701,215,442.73
补充资料:
  净利润-70,905,477.14-109,819,819.3
  资产减值准备-8,308,552.96-21,644,970.29
  固定资产和投资性房地产折旧-35,748,942.78-69,890,289.2
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-35,748,942.78-69,890,289.2
  无形资产摊销-2,256,109.66-4,008,360.44
  长期待摊费用摊销-5,994,118.06-12,059,616.34
  处置固定资产、无形资产和其他长期资产的损失-25,422.09--12,516.02
  公允价值变动损失--372,000.14--2,341,561.65
  财务费用-915,290.03--2,704,589.07
  投资损失--1,351,054.93--8,003,815.54
  递延所得税--2,807,207.92--5,339,895.82
  其中:递延所得税资产减少--3,617,398.16--4,129,748.32
    递延所得税负债增加-810,190.24--1,210,147.5
  存货的减少--8,045,852.22--7,104,922.03
  经营性应收项目的减少--73,266,368.56--91,325,148.82
  经营性应付项目的增加--39,999,279.4--27,480,862.13
  其他-1,908,565.55-2,977,476.74
  不涉及现金收支的投资和筹资活动金额其他项目---5,131,149.03
  现金的期末余额-521,984,091.85-701,215,442.73
  减:现金的期初余额-701,215,442.73-559,993,213.15
  现金及现金等价物的净增加额--179,231,350.88-141,222,229.58
公告日期2025-10-232025-08-232025-04-262025-04-26
审计意见(境内)标准无保留意见
TOP↑